Tower Research Capital LLC TRC Grows Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Tower Research Capital LLC TRC raised its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 1,376.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,436 shares of the company's stock after acquiring an additional 13,458 shares during the period. Tower Research Capital LLC TRC's holdings in Vaxcyte were worth $1,182,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. MML Investors Services LLC purchased a new position in Vaxcyte during the third quarter valued at approximately $260,000. Virtu Financial LLC acquired a new position in shares of Vaxcyte in the 3rd quarter valued at $355,000. Sanctuary Advisors LLC purchased a new stake in Vaxcyte during the third quarter worth $507,000. Franklin Resources Inc. grew its position in Vaxcyte by 13.2% during the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after buying an additional 324,560 shares during the period. Finally, Lord Abbett & CO. LLC increased its holdings in Vaxcyte by 26.9% in the third quarter. Lord Abbett & CO. LLC now owns 312,425 shares of the company's stock valued at $35,701,000 after buying an additional 66,183 shares in the last quarter. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Price Performance

NASDAQ PCVX traded down $1.59 during mid-day trading on Friday, hitting $32.92. The stock had a trading volume of 1,638,022 shares, compared to its average volume of 1,234,781. The firm's 50 day moving average is $55.57 and its 200 day moving average is $79.90. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of -7.16 and a beta of 1.26. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last quarter, insiders sold 24,000 shares of company stock valued at $1,946,720. Corporate insiders own 3.10% of the company's stock.

Wall Street Analyst Weigh In

PCVX has been the topic of several recent analyst reports. Bank of America lowered their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Guggenheim restated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Cantor Fitzgerald began coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating on the stock. Finally, The Goldman Sachs Group cut their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.